S5 Ep137: Living the Ex-Pat Life with Brooke Rasmussen, Pt. 1

Show Notes- On today's episode of CTL, we have the first of a special two-part series with MacKenzie Koppa and her high-school friend Brooke Rasmussen. Brooke and her husband, along with their seven children, have lived around the world. Today, MacKenzie and Brooke chat all about what it was like to move to so many unique places and adjust to many different cultures.

Brooke talks about their first tour when her husband was a diplomat in Eritrea, Africa Learning to live with less, especially where food is concerned Changing her perspective on pity versus generosity Equipping their family to handle future challenges Learning that language is not always that big of a barrier Shifting perspective on chasing beauty by cultural standards

The transition from Africa to Poland, in the States for training Brooke talks about life in Warsaw, Poland Ease of travel and abundance of food Enjoying the history and cultures in and around Poland Getting used to having babies amidst transition periods The blessing of having friends nearby for the kids

The difference in other cultures' views on family size Returning to the U.S. for a home assignment The decision to take an assignment in Jerusalem

Tune in next week to hear the rest of MacKenzie and Brooke's discussion and find out about the Rasmussen's time in Jerusalem, plus so much more!

Find MacKenzie- You can find MacKenzie Koppa on Instagram, Facebook, and the CTL Facebook Group, of course! You can also listen to her family-friendly podcast The Same Page!

Thanks to Our Sponsors- Today's episode of CTL is brought to you by Policy Genius. Go to PolicyGenius.com to find the right coverage for you and your family.

This week's episode is also sponsored by EverlyWell. For 15% OFF you own at home lab test kit, go to EverlyWell.com/LOVELY and enter code LOVELY at checkout.

Cultivating the Lovely is also sponsored by Plan to Eat meal planning service. Visit PlanToEat.com/LOVELY to start your free 60-day trial instead of the normal 30-day trial.